Treatment tolerance, tumor response, and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small cell lung cancer (NSCLC) in Chinese patients.

e19138 Background: Previously reported superior tumor response associated with platinum/pemetrexed in the first-line setting for for advanced non-squamous NSCLC has not been confirmed in real-world clinical settings. Methods: Patients receiving platinum-based doublets in the first-line setting for advanced non-squamous NSCLC in four Chinese tertiary care hospitals from 2007 to 2012 were retrospectively identified. Propensity score methods created matched treatment groups for platinum/pemetrexed versus other platinum-based doublets respectively for head-to-head comparisons on treatment tolerance (treatment cycles > or = 4), tumor control (partial response or stable disease), and adverse events. Results: Matching platinum/pemetrexed with other four doublets produced 95 docetaxel, 118 paclitaxel, 199 gemcitabine, and 72 vinorelbine pairs respectively. When compared to the other studied four doublets, platinum/pemetrexed had significantly higher rates of treatment tolerance (rate ratio (RR) ranged from 1.404 ...